

Biotech Daily

Monday January 1, 2018

Special Edition

2017: BDI-40 UP 7%; ASX200 2%, BIG CAPS 33%, NBI 21%

The Biotech Daily Top-40 Index (BDI-40) climbed 6.8 percent in the year to December 31 2017, compared to the S&P ASX200 up 1.6 percent, while the three Big Caps of Cochlear, CSL and Resmed (which are not in the BDI-40) climbed 33.25 percent for the 12 months.

Due to unforeseen circumstances, the BDI-40 January 1, 2017 data was not captured and the comparison is with an average of the November 30, 2016 and January 31, 2017 data. The same is the case for the Big Caps, while the ASX and Nasdaq Biotechnology Index (NBI) comparisons are for the 12-month time period (see charts below).

For the 12 months to December 31, 2017, the NBI climbed 21.1 percent.

In the month to December 31, 2017, the BDI-40 was up 8.0 percent, the ASX200 climbed 7.0 percent, the Big Caps eased 2.0 percent to their second highest market capitalizations and the NBI was up 1.5 percent.

Twenty-four of the Biotech Daily Top 40 companies were up, 13 fell and three were unchanged in December. Six companies added more than \$50 million each to the index.

Sirtex ended its annus horribilius of 2017 as the biggest of the biotechs, at a market capitalization of \$921 million, just ahead of Pro Medicus at \$901 million, with Nanosonics third at \$829 million.

December was generally a quiet month for biotechnology companies, with a raft of small rises in the BDI-20 and small falls in the Second 20.


Uscom was the best by percentage, up \$12 million or 70.6 percent to \$29 million, followed by Polynovo (37.1%), Pro Medicus (15.5%), Neuren (15.2%), Viralytics (14.5%), Medical Developments (13.4%), Nanosonics (9.1%) and Sirtex (7.1%).

LBT led the falls, down 22.2 percent to \$28 million, followed by Dimerix (14.3%), Psivida (13.0%), Universal Biosensors (11.7%) and Immutep (Prima) down 10.2 percent.


Outside the BDI-40, a number of companies made significant gains in 2017, with Bioxyne climbing from \$4 million to \$59 million, Creso Pharma rising from \$7 million to \$79 million and Noxopharm improving from \$20 million to \$64 million.

On the Nasdaq, Aviragen (formerly Biota) continued its fall to \$28 million, while Protagonist hit a record high of \$545 million and Redhill slipped \$2 million to \$140 million.


BDI-40 v ASX200 Jun 30, 2006 to Dec 31, 2017 - Adjusted



BDI-40 v ASX200 Nov 30, 2016 to Dec 31, 2017



Big Caps \$m (Cochlear, CSL, Resmed) Nov 30, 2016 - Dec 31, 2017



Biotech Daily Top 40 with Market Capitalization

Company \$Am	Dec-16	Dec-17	Jan-18
Cochlear	6,817	10,400	9,854
CSL	44,684	64,828	63,906
Resmed	11,694	15,976	15,635
BDI-20			
Airxpanders	268	201	209
Bionomics	176	193	186
Clinuvel	384	384	391
Compumedics	131	75	74
Ellex	181	133	138
Impedimed	457	364	384
Medical Developments	258	372	423
Mesoblast	462	635	687
Nanosonics	1,000	760	829
Neuren	116	276	318
Opthea	112	146	141
Pharmaxis	88	82	82
Polynovo	155	248	340
Immutep (Prima)	77	59	53
Pro Medicus	553	780	901
Psivida	85	77	67
Reva	475	264	280
Sirtex	1,594	860	921
Telix	12	128	120
Viralytics	274	145	166
Second 20			
Acrux	52	25	25
Actinogen	30	28	29
Admedus	91	74	75
Avita	86	66	64
Benitec	17	40	41
Cyclopharm	54	64	65
Dimerix	12	14	12
Factor Therapeutics	58	37	37
Genetic Signatures	47	31	33
ITL Health	25	42	44
LBT Innovations	45	36	28
Oncosil	45	73	76
Optiscan	19	40	43
Orthocell	29	28	27
Osprey	111	144	139
Prana	29	37	38
Starpharma	243	519	504
Universal Biosensors	52	60	53
Uscom	23	17	29
Volpara	47	61	66
	.,	0.	00

^{*} Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan, Telix, Volpara and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in a range of other biotechnology companies: http://www.australianethical.com.au/who-we-invest-in. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053 email: editor@biotechdaily.com.au; www.biotechdaily.com.au; <a href="mailto:www.biotechdaily.com.au; <a href="mailto:www.biote